Sarepta Therapeutics Inc. (SRPT)

120.82
4.64 3.70
NASDAQ : Health Technology
Prev Close 125.46
Open 125.00
Day Low/High 118.75 / 126.01
52 Wk Low/High 50.68 / 176.50
Volume 1.15M
Avg Volume 1.09M
Exchange NASDAQ
Shares Outstanding 66.82M
Market Cap 8.89B
EPS -0.90
Div & Yield N.A. (N.A)

Latest News

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Netflix Is Tonight's Big Report: Here's How I Would Play It

Netflix Is Tonight's Big Report: Here's How I Would Play It

This is a battleground stock that has made big moves in both directions on earnings in the past.

The Market Is Not Embracing JPMorgan's Optimism

The Market Is Not Embracing JPMorgan's Optimism

The pressure on financials is affecting the entire market.

Square Continues to See Extreme Pressure

Square Continues to See Extreme Pressure

If you are interested in Square longer term be patient and wait for the drama to end.

Intel Regains Its Leadership Position in the Semiconductor Sector

Intel Regains Its Leadership Position in the Semiconductor Sector

The stock still needs to do more work to be convincing.

Overall Market Breadth Remains Negative

Overall Market Breadth Remains Negative

I'm not yet convinced that this poor action is the start of a major change in market character.

PepsiCo Isn't Going Anywhere Soon

PepsiCo Isn't Going Anywhere Soon

Blue chip name PEP is a good example of the weak action in individual stocks.

There's Nothing Very Attractive About GE

There's Nothing Very Attractive About GE

It's an interesting story but there are better places for your funds.

Play Sarepta Therapeutics' Climb This Way

Play Sarepta Therapeutics' Climb This Way

This options trade gives the position plenty of time to work.

Alphabet Before Congress, Fed Decision Make for an Interesting Day

Alphabet Before Congress, Fed Decision Make for an Interesting Day

Traders are likely remembering what Facebook stock did when Mark Zuckerberg testified before Congress.

Sears Has Become a Disaster

Sears Has Become a Disaster

It is the poster boy for the havoc that internet retailers have wrecked on brick and mortar retailers.

Corrective Action in This Market Is Often Quite Hidden

Corrective Action in This Market Is Often Quite Hidden

The indices are being jerked around on some news headlines today.

There Is No Rush to Buy Micron

There Is No Rush to Buy Micron

It's not different this time, semiconductors are still cyclical.

Six Biotechnology Names on My Watch List

Six Biotechnology Names on My Watch List

After recent weakness in the biotech sector, here are some names to start watching.

Parent Project Muscular Dystrophy And Sarepta Therapeutics Partner To Launch Duchenne Outcomes Research Interchange, A Patient-Data Warehouse Serving The Entire Duchenne Community

Parent Project Muscular Dystrophy And Sarepta Therapeutics Partner To Launch Duchenne Outcomes Research Interchange, A Patient-Data Warehouse Serving The Entire Duchenne Community

Building on PPMD's 10-Year-Old Duchenne Registry, the largest Patient Reported Outcomes Registry for the Disease, and Sarepta Therapeutics' Leadership with the First U.S.-Approved Therapy, New Interchange is Scheduled for 2019 Launch

The Market Is Finally Pulling Back

The Market Is Finally Pulling Back

This is a healthy pullback in a market that was a little overheated.

Coffee Acquisition or Not, Coca-Cola Doesn't Have Much Fizz

Coffee Acquisition or Not, Coca-Cola Doesn't Have Much Fizz

Despite $5.1 billion deal for Costa, I'm not slurping any KO up.

A Lesson to Learn From Thursday's Market Action

A Lesson to Learn From Thursday's Market Action

You don't have to be Sigmund Freud to understand the psychology here.

HPE: Surpassing Expectations, Raising Guidance Incrementally

HPE: Surpassing Expectations, Raising Guidance Incrementally

If estimates continue to come up there will be institutional interest in the stock.

3 Stock Trades I'm Looking to Make on the U.S.-Mexico Trade Deal

3 Stock Trades I'm Looking to Make on the U.S.-Mexico Trade Deal

There are several key points to keep in mind as you digest this news.

Fear of Missing Out Outweighs Fear of Trump Political Fallout

Fear of Missing Out Outweighs Fear of Trump Political Fallout

If the market wanted an excuse to sell off it had it.

Don't Chase Walmart Here

Don't Chase Walmart Here

After rallying to more than $100 a share, the stock could pull back to around $95 before consolidating gains.

Prepare For the Worst but Stay Positive

Prepare For the Worst but Stay Positive

The market has wanted to sell-off for a while and finally it is doing it.

Little Fear of Missing Out as Stocks Hold Gains

Little Fear of Missing Out as Stocks Hold Gains

While markets are higher Tuesday, there is little to suggest recent choppy action won't continue.

Fears Over Turkey Ease, but Don't Expect a Strong Market Uptrend

Fears Over Turkey Ease, but Don't Expect a Strong Market Uptrend

The bounce this morning is producing a sigh of relief, but this is going to remain a difficult trading market.

Overly Aggressive Dip Buyers Finally Trapped

Overly Aggressive Dip Buyers Finally Trapped

For a long time now one of the most consistent patterns in the market has been buying dips created by negative headlines.

Strength in Growth Names Is Giving the Market a More Upbeat Feel

Strength in Growth Names Is Giving the Market a More Upbeat Feel

Apple in particular is helping the bullish cause.

Sarepta Therapeutics, Inc. And CureDuchenne To Host Webinar On Duchenne Muscular Dystrophy Programs Utilizing Sarepta's RNA-Targeted Technology Platforms

Sarepta Therapeutics, Inc. And CureDuchenne To Host Webinar On Duchenne Muscular Dystrophy Programs Utilizing Sarepta's RNA-Targeted Technology Platforms

Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, and non-profit CureDuchenne announced today they have...

TheStreet Quant Rating: D (Sell)